|
DE3733478A1
(de)
*
|
1987-10-01 |
1989-04-13 |
Schering Ag |
Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
|
|
EP0310542B1
(de)
*
|
1987-10-01 |
1994-06-08 |
Schering Aktiengesellschaft |
Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
|
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
|
GB8813353D0
(en)
*
|
1988-06-06 |
1988-07-13 |
Ici Plc |
Therapeutic product
|
|
US5393785A
(en)
*
|
1988-10-31 |
1995-02-28 |
Endorecherche, Inc. |
Therapeutic antiestrogens
|
|
HU208150B
(en)
*
|
1988-10-31 |
1993-08-30 |
Endorecherche Inc |
Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
|
|
US5686465A
(en)
*
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
|
US5395842A
(en)
*
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
|
FR2643638B1
(fr)
*
|
1989-02-24 |
1991-06-14 |
Roussel Uclaf |
Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
|
EP0462189B1
(de)
*
|
1989-03-10 |
1995-09-27 |
Endorecherche Inc. |
Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen
|
|
ES2189784T3
(es)
*
|
1989-07-07 |
2003-07-16 |
Endorech Inc |
Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
|
|
AU5856090A
(en)
*
|
1989-07-07 |
1991-02-06 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
|
DE3925507A1
(de)
*
|
1989-07-28 |
1991-01-31 |
Schering Ag |
14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
|
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
JPH07506575A
(ja)
*
|
1992-05-21 |
1995-07-20 |
アンドルシェルシュ・インコーポレイテッド |
テストステロン5α−レダクターゼ活性の阻害剤
|
|
DE19622457A1
(de)
|
1996-05-24 |
1997-11-27 |
Schering Ag |
7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US5866560A
(en)
*
|
1996-08-20 |
1999-02-02 |
Schering Ag |
7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
|
|
DE19635525A1
(de)
*
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US6355630B1
(en)
|
1997-10-23 |
2002-03-12 |
American Home Products Corporation |
Estra-1,3,5(10)-triene-7α-thioethers
|
|
CA2308773A1
(en)
*
|
1997-10-23 |
1999-04-29 |
Ivo Jirkovsky |
Estra-1,3,5(10)-triene-7alpha-thioethers
|
|
AR015500A1
(es)
*
|
1997-12-23 |
2001-05-02 |
Schering Ag |
11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
|
|
DE19807791A1
(de)
|
1998-02-19 |
1999-08-26 |
Schering Ag |
Kombinationspräparat aus Östrogen und Antiöstrogen
|
|
ATE473759T1
(de)
|
1998-05-22 |
2010-07-15 |
Univ Leland Stanford Junior |
Bifunktionelle moleküle sowie darauf basierende therapien.
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
DE10027887A1
(de)
*
|
2000-05-31 |
2001-12-13 |
Jenapharm Gmbh |
Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
|
|
AU2001267904A1
(en)
|
2000-06-30 |
2002-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Novel antiandrogenic agent
|
|
GB0025221D0
(en)
*
|
2000-10-14 |
2000-11-29 |
Astrazeneca Ab |
New process
|
|
US20050084908A1
(en)
*
|
2000-11-06 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
|
|
LT2762140T
(lt)
|
2001-02-19 |
2017-06-26 |
Novartis Ag |
Solidinių smegenų navikų gydymas rapamicino dariniu
|
|
BR0209647A
(pt)
|
2001-05-16 |
2004-07-27 |
Novartis Ag |
Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
|
|
GB0123961D0
(en)
*
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
|
DE10159217A1
(de)
*
|
2001-11-27 |
2003-06-05 |
Schering Ag |
17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
|
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
|
CA2483594C
(en)
|
2002-05-16 |
2011-02-15 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
|
NZ536475A
(en)
*
|
2002-05-24 |
2008-06-30 |
Schering Corp |
Neutralizing human anti-igfr antibody
|
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
CN100395259C
(zh)
*
|
2004-04-28 |
2008-06-18 |
江苏豪森药业股份有限公司 |
甾体类衍生物
|
|
US20050277625A1
(en)
*
|
2004-05-21 |
2005-12-15 |
Ralf Wyrwa |
Estriol and estetrol prodrugs
|
|
US7534780B2
(en)
*
|
2004-05-21 |
2009-05-19 |
Bayer Schering Pharma Aktiengesellschaft |
Estradiol prodrugs
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
EP1771462B1
(de)
*
|
2004-07-27 |
2010-09-29 |
Sicor Inc. |
Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
|
|
CA2594477C
(en)
|
2005-01-21 |
2016-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
US20060233810A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Yaolin Wang |
Methods and compositions for treating or preventing cancer
|
|
CN102379684B
(zh)
|
2005-04-28 |
2014-11-19 |
普罗透斯数字保健公司 |
药物信息系统
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US9062126B2
(en)
|
2005-09-16 |
2015-06-23 |
Raptor Pharmaceuticals Inc. |
Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
|
|
CA2623034A1
(en)
|
2005-09-27 |
2007-04-05 |
Novartis Ag |
Carboxyamine compounds and their use in the treatment of hdac dependent diseases
|
|
MX2007006653A
(es)
*
|
2005-10-05 |
2009-02-17 |
Sicor Inc |
Separacion de isomeros de fulvestrant.
|
|
EP2275103B1
(de)
|
2005-11-21 |
2014-04-23 |
Novartis AG |
mTOR-Inhibitoren in der Behandlung endokriner Tumore
|
|
US20070197488A1
(en)
*
|
2005-11-29 |
2007-08-23 |
Olaf Peters |
Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
|
|
US20070123500A1
(en)
*
|
2005-11-29 |
2007-05-31 |
Gerd Mueller |
Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
|
|
US20070135399A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Heteroaromatic sulphonamide prodrugs
|
|
US20070135375A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Sulfamoyl sulfonate prodrugs
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
CN102861338A
(zh)
|
2006-04-05 |
2013-01-09 |
诺瓦提斯公司 |
用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
|
|
JP2009532503A
(ja)
|
2006-04-05 |
2009-09-10 |
ノバルティス アクチエンゲゼルシャフト |
癌を処置するための治療剤の組合せ
|
|
US20090317489A1
(en)
|
2006-05-09 |
2009-12-24 |
Hanspeter Nick |
Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
|
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
EP2491923A3
(de)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Kombinationen therapeutischer Wirkstoffe zur Krebsbehandlung
|
|
WO2009039700A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Xi'an Libang Pharmaceutical Co., Ltd. |
Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentvlsulphinvl) nonvllestra-l,3,5-(10)- triene-3,17-beta-diol
|
|
US20090082323A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched fulvestrant
|
|
SG185311A1
(en)
|
2007-10-16 |
2012-11-29 |
Repros Therapeutics Inc |
Trans-clomiphene for metabolic syndrome
|
|
EP2070941A1
(de)
|
2007-12-14 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Stereoselektive Synthese von selektiven negativen Regulatoren von Östrogenrezeptoren
|
|
CA2716576A1
(en)
|
2008-03-07 |
2009-09-11 |
Nageswara R. Palepu |
Fulvestrant formulations
|
|
AU2009228765B2
(en)
|
2008-03-24 |
2012-05-31 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
PT2260020E
(pt)
|
2008-03-26 |
2014-10-28 |
Novartis Ag |
Inibidores das desacetilases b baseados no hidroxamato
|
|
US8063249B1
(en)
|
2008-04-25 |
2011-11-22 |
Olema Pharmaceuticals, Inc. |
Substituted triphenyl butenes
|
|
WO2010043404A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Synthon B.V. |
Processes and intermediates for the production of fulvestrant
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
EP2398500B1
(de)
|
2009-02-20 |
2019-03-13 |
2-BBB Medicines B.V. |
Arzneiabgabesystem auf glutathion-basis
|
|
ES2942923T3
(es)
|
2009-05-06 |
2023-06-07 |
Laboratory Skin Care Inc |
Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
|
|
EP2258375A1
(de)
|
2009-06-04 |
2010-12-08 |
Bayer Schering Pharma Aktiengesellschaft |
17B-alkyl-17alpha-oxy-estratriene
|
|
WO2010151133A1
(en)
|
2009-06-25 |
2010-12-29 |
Erasmus University Medical Center Rotterdam |
Methods for establishing and predicting resistance to endocrine therapy using an mirna profile
|
|
MA33451B1
(fr)
|
2009-06-26 |
2012-07-03 |
Novartis Ag |
Dérivés d'imidazolidin-2-one 1,3-disubstitués en tant qu'inhibiteurs de cyp 17
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
AU2010288534A1
(en)
|
2009-08-26 |
2012-03-15 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
|
|
AU2010294209A1
(en)
|
2009-09-10 |
2012-03-29 |
Irm Llc |
Ether derivatives of bicyclic heteroaryls
|
|
MY156209A
(en)
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
|
JP5456908B2
(ja)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
ヘテロ環式スルホンアミド誘導体
|
|
AU2012265844A1
(en)
|
2009-12-08 |
2013-05-02 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
EP2582681A1
(de)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Piperidinylsubstituierte 1,3-dihydro-benzoimidazol-2-ylidenaminderivate
|
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
|
|
BR112013018534B1
(pt)
|
2011-01-20 |
2021-04-06 |
Board Of Regents, The University Of Texas System |
Agente de contraste, seus métodos de preparação, e produto de combinação
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
|
CN103492390A
(zh)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
|
EA023064B1
(ru)
|
2011-04-28 |
2016-04-29 |
Новартис Аг |
ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
|
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
EP2721007B1
(de)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl-isochinolinon-verbindungen
|
|
CA2840315A1
(en)
|
2011-06-27 |
2013-01-03 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
EP2791128A4
(de)
|
2011-12-16 |
2015-04-22 |
Olema Pharmaceuticals Inc |
Neue benzopyranverbindungen, zusammensetzungen daraus und verwendungen davon
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
MY170922A
(en)
|
2011-12-22 |
2019-09-18 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
|
US9126979B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
CN104125955A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
|
CN104125953A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
|
CN104136429A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
|
AU2012355615A1
(en)
|
2011-12-23 |
2014-07-10 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
|
KR20140117457A
(ko)
|
2012-01-31 |
2014-10-07 |
노파르티스 아게 |
Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
|
|
US20150031656A1
(en)
|
2012-02-29 |
2015-01-29 |
Repros Therapeutics Inc. |
Combination therapy for treating androgen deficiency
|
|
US11179468B2
(en)
|
2012-04-09 |
2021-11-23 |
Eagle Pharmaceuticals, Inc. |
Fulvestrant formulations
|
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
|
BR112015007083A2
(pt)
|
2012-10-02 |
2017-07-04 |
Epitherapeutics Aps |
inibidores de histona demetilases
|
|
JP2016027000A
(ja)
*
|
2012-10-09 |
2016-02-18 |
学校法人早稲田大学 |
ステロイド化合物及びこれを含有する医薬
|
|
EP2909224B1
(de)
|
2012-10-22 |
2020-03-18 |
Intas Pharmaceuticals Limited |
Verbessertes verfahren zur herstellung von fulvestrant
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
|
CN104936971B
(zh)
*
|
2013-04-18 |
2017-10-13 |
西安力邦医药科技有限责任公司 |
具有抗癌活性的7‑α‑[9‑(4,4,5,5,5‑五氟戊基亚硫酰基)壬基]‑雌甾‑1,3,5(10)‑三烯‑3,17β‑二醇的酯类衍生物及其制备方法
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
EP3046921A4
(de)
|
2013-09-22 |
2017-02-22 |
Calitor Sciences, LLC |
Substituierte aminopyrimidinverbindungen und verfahren zur verwendung
|
|
EP3094340A1
(de)
|
2014-01-15 |
2016-11-23 |
Novartis AG |
Pharmazeutische kombinationen
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されたヘテロアリール化合物および使用方法
|
|
EP3126345A1
(de)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitoren von histondemethylasen
|
|
CN103980336B
(zh)
*
|
2014-05-21 |
2016-10-05 |
天津孚音生物科技发展有限公司 |
一种新的氟维司群的合成方法
|
|
CN103965280B
(zh)
*
|
2014-05-21 |
2016-04-20 |
天津孚音生物科技发展有限公司 |
一种氟维司群中间体的制备方法
|
|
WO2015181116A1
(en)
|
2014-05-26 |
2015-12-03 |
Crystal Pharma, S.A.U. |
Process and intermediades for the preparation of 7-alkylated steroids
|
|
EA201790154A1
(ru)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Соединения и способы для ингибирования гистоновых деметилаз
|
|
EP3347097B1
(de)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
|
|
DK3355884T3
(da)
|
2015-10-01 |
2021-08-02 |
Olema Pharmaceuticals Inc |
Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
|
|
EP3373967B9
(de)
|
2015-11-10 |
2023-10-04 |
Paracrine Therapeutics AB |
Behandlung von er-negativem brustkrebs mit einem pdgf-cc-inhibitor und einem antiöstrogen
|
|
ES2935125T3
(es)
|
2015-12-09 |
2023-03-01 |
Univ Illinois |
Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
|
|
WO2018017410A1
(en)
|
2016-07-22 |
2018-01-25 |
Eli Lilly And Company |
Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
AR110728A1
(es)
|
2017-01-06 |
2019-04-24 |
G1 Therapeutics Inc |
Terapia combinada para el tratamiento del cáncer
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CA3144791A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
US20230119759A1
(en)
|
2020-03-10 |
2023-04-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
|
|
IT202100003176A1
(it)
|
2021-02-12 |
2022-08-12 |
Farmabios Spa |
Processo per la preparazione di fulvestrant
|
|
CN114716496B
(zh)
*
|
2022-04-29 |
2024-04-02 |
香港中文大学(深圳) |
氟维司群衍生物及氟维司群衍生物制备方法和应用
|
|
CN117534720A
(zh)
*
|
2022-08-01 |
2024-02-09 |
香港中文大学(深圳) |
环戊烷多氢菲衍生物及其制备方法和应用
|
|
CN116041412A
(zh)
*
|
2023-01-13 |
2023-05-02 |
香港中文大学(深圳) |
氟维司群衍生物及其制备方法、应用和治疗乳腺癌的药物
|
|
CN117050132A
(zh)
*
|
2023-04-28 |
2023-11-14 |
香港中文大学(深圳) |
甾体类衍生物、制备方法、应用和治疗乳腺癌的药物
|
|
CN116535454A
(zh)
*
|
2023-04-28 |
2023-08-04 |
香港中文大学(深圳) |
氟维司群类化合物及其制备方法和应用
|